By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is largely bearish on IBM's stock, with key concerns being the long-dated and uncertain timeline for quantum computing revenue, the risk of multiple compression if AI hype cools, and the persistent margin pressure on IBM's core business.
Risk: The potential for a 30%+ drawdown due to a re-rating narrative disconnect from near-term earnings and a cooling AI-hype cycle.
Opportunity: The real potential of quantum computing, if the software ecosystem and enterprise demand materialize fast.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
International Business Machines (IBM) stock extended its gain on June 1 after Barclays analyst Raimo Lenschow initiated coverage of the AI infrastructure firm with an “Overweight” rating.
In his research note, Lenschow told clients that IBM could be trading at $350 by year-end, a bullish price target that signals potential upside of nearly 10% from current levels.
- Microsoft Stock Is Up Nearly 30% From Its March Lows, But You Shouldn’t Sell MSFT Just Yet
- Dell Stock Could Be Worth 30% More - Based on Strong AI Demand and FCF
Barclays’ constructive view on IBM shares is particularly significant given they’re already up a remarkable 45% versus their year-to-date low.
Lenschow’s bullish thesis on IBM stock rests mostly on its massive leap into quantum computing.
Last week, the company announced plans to invest more than $10 billion in quantum computing over the next five years as part of its broader commitment to launching a large-scale commercial quantum system by 2029.
This disclosure came shortly after the U.S. government awarded IBM with $1 billion in funding to accelerate quantum computing development.
IBM then pledged to contribute another $1 billion to establish a new spinout, Anderon, which will oversee the construction and operation of the new quantum infrastructure.
In his report, the Barclays analyst framed this as a strategic option on what could become the next major computing paradigm.
According to Lenschow, IBM is following Nvidia’s (NVDA) playbook in the quantum market — building the software tools and developer ecosystem needed to drive mass adoption.
“IBM has a compelling opportunity ahead around quantum computing that could accelerate growth if successful,” he added.
In Barclays’ most optimistic bull case, IBM shares could reach $449, which would represent a 40% return from current levels, on top of a 2.11% dividend yield.
Note that IBM currently sits firmly above its key moving averages (MAs), with an RSI in the early 80s, reinforcing a very strong uptrend, unlikely to subside without a meaningful catalyst.
Other Wall Street analysts also agree with Lenschow’s bullish thesis on IBM stock, believing its software business is much less exposed to AI disruption than some of its enterprise peers as well.
Four leading AI models discuss this article
"The core driver—commercial quantum profitability by 2029—remains highly uncertain; without a monetization path, upside hinges on a rare confluence of rapid tool adoption, ecosystem build-out, and sustained funding."
IBM's bull thesis hinges on quantum computing moving from hype to revenue by 2029, backed by $10B capex, a $1B government grant, and a spinout called Anderon. Barclays’ Overweight with a potential 40% upside and a $350-$449 path sounds plausible only if the software ecosystem and enterprise demand materialize fast. Yet the path is long-dated and uncertain: commercial quantum tools remain in early adopter stages, ROI depends on multi-year software tooling, and execution risk around the 2029 system is non-trivial. With momentum trading and a high RSI, a disappointing quantum milestone could reprice IBM stock quickly, even as AI cycles rage on.
The strongest counterpoint is that quantum computing remains a high-uncertainty, long-duration bet; a delay or slower enterprise adoption could erase upside, leaving investors years from meaningful profit.
"The current valuation is pricing in speculative quantum breakthroughs that are years away, ignoring the reality of IBM's slow-growth legacy business model."
The market is conflating long-term R&D 'optionality' with immediate fundamental value. While IBM's pivot to hybrid cloud and AI-driven consulting is stabilizing, pinning a $350 price target on speculative quantum infrastructure—which won't reach commercial scale until 2029—is a massive leap of faith. IBM’s core revenue growth remains sluggish compared to high-growth peers. With an RSI above 80, the stock is technically overbought, suggesting the recent rally is driven more by momentum and 'AI-tag' sentiment than actual earnings expansion. Investors should be wary of paying a premium for quantum dreams while the legacy software and consulting segments face persistent margin pressure in a high-rate environment.
If IBM successfully captures the first-mover advantage in quantum error correction, they could effectively create a 'moat' around the entire enterprise computing sector that renders current P/E valuations irrelevant.
"IBM's quantum upside is real but priced-in already; the 10% near-term target underestimates either the bull case or the risk of a pullback after a 45% YTD rally on an unproven revenue stream."
The quantum computing narrative is real, but Lenschow's $350 target (10% upside) is oddly conservative given the 45% YTD run and his own $449 bull case. That gap suggests either caution or anchoring to current momentum. More critically: IBM's quantum revenue is zero today and won't materialize meaningfully until 2028–2030 at earliest. The $10B commitment is real, but it's capex, not earnings accretion. Meanwhile, IBM's core business (hybrid cloud, software) faces margin pressure from AI-driven commoditization. The article conflates 'strategic option' with 'near-term catalyst.' RSI in the 80s signals exhaustion risk, not strength. A 10% target after a 45% move feels like the analyst is late to the party.
If IBM executes quantum-as-a-service by 2027–2028 and captures even 5–10% of an emerging $50B+ market, the stock could justify $400+ without relying on legacy business recovery. The quantum play isn't vaporware—it's funded, government-backed, and IBM has genuine IP moats here.
"Quantum revenue impact for IBM is unlikely before 2028, so the $350 target overstates near-term upside from current levels."
Barclays' $350 year-end target for IBM rests on a $10B quantum bet and 2029 commercialization timeline, yet this ignores that meaningful revenue from quantum remains years away and highly uncertain. IBM's hybrid cloud and consulting segments continue facing margin pressure from AWS and Azure competition, while its AI infrastructure exposure is narrower than Nvidia or Dell. The 45% YTD gain and RSI near 80 already embed substantial optimism; any delay in quantum milestones or slower software growth could trigger a reversal rather than extension of the rally.
The $1B U.S. government award plus IBM's matching commitment materially lowers execution risk and could accelerate ecosystem adoption faster than modeled, validating the Nvidia-like playbook thesis.
"Execution risk in software/tools and enterprise adoption timing by 2029 could erode upside even with government support and capex."
Claude's claim that a $350 target is conservative ignores the real risk: the value hinge is not just quantum hype but the software stack and enterprise adoption timing. Execution risk around quantum tooling, ecosystem partners, and ROI realization by 2029 could erase upside even with a government grant and capex. Momentum and RSI won't shield IBM if the quantum-to-revenue transition stalls; markets may misprice timing versus long-run optionality.
"IBM's current valuation reflects a speculative multiple expansion that is highly vulnerable to a broader AI-sector sentiment correction, regardless of quantum execution."
Claude, your focus on the $350 target being 'conservative' misses the structural issue: IBM's valuation is currently tethered to a 're-rating' narrative, not just earnings. If the market treats IBM as a quantum-AI utility rather than a legacy consulting firm, the P/E expansion is disconnected from near-term revenue. The real risk isn't just quantum delay; it's the potential for a multiple compression if the broader AI-hype cycle cools, regardless of IBM's specific quantum milestones.
"IBM's current valuation depends on sustained AI-quantum narrative momentum, not quantum revenue; narrative collapse is a bigger risk than execution delay."
Gemini's multiple-compression risk is the real tail risk nobody's quantified. If AI hype cools and IBM's quantum timeline slips even 12 months, the stock doesn't just revert to legacy valuations—it could undershoot them. ChatGPT and Claude both focus on quantum execution risk, but Gemini's point that IBM is being re-rated as a *narrative* rather than earnings is the mechanism for a 30%+ drawdown. That's the asymmetric risk worth hedging.
"AI-hype cooling plus legacy margin pressure creates faster downside than Claude's narrative mechanism alone implies."
Claude ties the 30% drawdown solely to narrative re-rating and AI-hype cooling, yet underweights how IBM's hybrid-cloud margins already face AWS/Azure pressure regardless of quantum timelines. A 12-month slip wouldn't just erase the premium—it could accelerate multiple compression if enterprise ROI proofs lag the $10B spend, exposing the grant's limited near-term impact on earnings.
The panel is largely bearish on IBM's stock, with key concerns being the long-dated and uncertain timeline for quantum computing revenue, the risk of multiple compression if AI hype cools, and the persistent margin pressure on IBM's core business.
The real potential of quantum computing, if the software ecosystem and enterprise demand materialize fast.
The potential for a 30%+ drawdown due to a re-rating narrative disconnect from near-term earnings and a cooling AI-hype cycle.